### **Overview** Sun Pharma Advanced Research Company Ltd. (SPARC) is a clinical-stage biopharmaceutical company and a part of the Sun Pharma Group, focused on innovation-driven research and development in therapeutics with high unmet medical need. Incorporated in 2006 as a spin-off from Sun Pharmaceutical Industries Limited (Sun Pharma), SPARC has evolved from a novel drug delivery systems (NDDS) platform into a globally oriented R&D innovator developing **New Chemical Entities (NCEs)** and **New Biological Entities (NBEs)**. The company operates across oncology, immunology, and neurodegeneration, leveraging a capital-efficient, science-led model with global R&D hubs in India and the U.S. As of late 2025, SPARC is strategically pivoting toward high-value, first-in-class assets, advancing a diversified pipeline, optimizing operational efficiency, and strengthening its business model through early partnerships and non-traditional collaboration structures. --- ### **Leadership & Governance** - **Anilkumar Raghavan** serves as CEO, responsible for driving SPARC’s transformation into a globally competitive pharmaceutical innovator. He joined SPARC in 2014 after leading Quintiles’ India and Sri Lanka operations. - Promoters, including **Dilip Shanghvi** and family entities (via Shanghvi Finance Private Limited), hold a **65.67% stake**, ensuring strategic continuity and financial support. - SPARC is a publicly listed company in India—the first R&D-focused pharma firm on the Indian exchange—while maintaining global R&D operations via its U.S. subsidiary **SPARCLIFE Inc.** (Delaware, established 2023). --- ### **R&D Strategy & Pipeline Focus (Nov 2025 Snapshot)** #### **Therapeutic Areas** SPARC’s pipeline strategy is now tightly concentrated in two high-growth therapeutic areas: - **Oncology** – with a strong focus on **tumor-targeted drug delivery**, including antibody-drug conjugates (ADCs), small molecule-drug conjugates (SMDCs), and **synthetic lethality** platforms. - **Immunology** – focused on **autoimmune dermatology**, particularly **alopecia areata (AA)** and **vitiligo**, with an emphasis on **topical small molecule therapies** to avoid systemic toxicity. Neurodegeneration programs (e.g., Vodobatinib for Parkinson’s) have been deprioritized following negative interim results from the PROSEEK trial, though the asset remains viable for **chronic myeloid leukemia (CML)**. #### **Core Pipeline Assets (2025 Status)** | **Asset** | **Indication** | **Mechanism** | **Development Status** | **Next Milestone** | |---------|--------------|--------------|----------------------|------------------| | **Vodobatinib (SCO-088)** | Refractory CML | BCR-ABL inhibitor (3rd-gen TKI) | Phase 2 complete; shifted to partnered development | Seeking commercial partner for registrational studies | | **SBO-154** | Solid tumors (MUC1+ cancers) | Anti-MUC1 ADC targeting SEA domain | Phase 1 active in U.S., Australia; IND filed in India | Dose escalation in 30-patient cohort; expansion in ER+ breast, lung, ovarian cancers | | **SCD-153** | Alopecia Areata, Vitiligo | Topical itaconate prodrug (immunomodulatory) | Phase 1a complete; Phase 1b enrolling patients | Early efficacy signal assessment in MAD study | | **SCO-155** | mCRPC | PSMA-targeted SMDC (small molecule-drug conjugate) | Licensеd to Tiller Therapeutics | IND expected in FY2026 | | **Vibozilimod (SCD-044)** | Psoriasis, Atopic Dermatitis | Selective S1PR1 agonist | Phase 2a/b trials complete; licensed to Sun Pharma | Topline data in Q1 FY26 | --- ### **Key Strategic Shifts (2024–2025)** #### **1. Portfolio Refocusing** - Transitioned from **NDDS/505(b)(2)** programs to **first-in-class NCEs and NBEs** – now over 80% of pipeline value. - Prioritizing **near-term cash-generating assets**: - Enforcing **orphan exclusivity and pediatric rare disease voucher (PRDV)** litigation for **Sezaby** (benzyl alcohol-free phenobarbital). - Monetizing **Priority Review Voucher (PRV)** potential from Sezaby approval. - Re-positioning **PDP-716** (glaucoma) with new API vendor; IND re-submission pending and target approval by **FY26**. #### **2. Innovation in Modalities & Platforms** - **MUC1-ADC Platform (SBO-154)**: - Targets the **SEA domain** of MUC1—a novel, underexploited epitope—avoiding interference from circulating MUC1 fragments. - High tumor specificity; broad applicability across epithelial cancers. - Platform potential: can be combined with **MMAE**, **immune agonists**, or **anti-angiogenesis payloads**. - **Small Molecule-Drug Conjugate (SMDC)**: - **SCO-155** uses a **PSMA-targeted ligand** to deliver cytotoxin; showed **complete tumor regression** in xenograft models at 60 mcg/kg. - Differentiated from radio-ligand therapies (e.g., Pluvicto) by using non-radioactive payloads suitable for outpatient infusion. - **Synthetic Lethality**: - Developing modular platform targeting PARP-resistant cancers using customizable linker-payload systems. #### **3. Agile Business Model & Partnerships** - **Tiller Therapeutics NewCo (Dec 2024)**: - Joint venture with **UCSF** and scientific founders to advance SCO-155 and future SMDCs. - SPARC holds **55% equity stake**; retains upside while de-risking development. - Represents a **scalable NewCo model** to spin out early-stage assets with external funding. - **Academic Collaborations**: - Ongoing partnerships with **UCSF**, **Johns Hopkins**, **Georgetown**, and **Tel Aviv University** (antibody licensing). - **Capability-Based Partnering**: - SPARC leverages its **translational R&D engine**, **bioinformatics**, and **clinical development expertise** to co-develop or out-license assets (e.g., SCD-044 to Sun Pharma for $145M total potential value). #### **4. Operational Efficiency & Cost Optimization** - Conducting **Phase 1a and Phase 1b trials for SCD-153 in India**, saving time and costs. - Utilizing **India-based R&D infrastructure** (Mumbai, Vadodara) to accelerate development. - **AI/ML and computational chemistry** integrated via partnerships with **Schrödinger, One Three Biotech**, and internal teams. --- ### **Pipeline Progress & Catalytic Events (2024–2025)** - **SBO-154**: - Received **FDA “Study May Proceed” letter** and initiated **multi-site Phase 1 trial** across U.S. and Australia. - Preclinical data show strong tumor targeting with **1,000-fold selectivity** for MUC1-SEA+ cells. - No competitors currently targeting MUC1-SEA in clinic; potential for tumor-agnostic development. - **SCD-153**: - Phase 1a in healthy volunteers confirmed **low systemic exposure and safety**. - Phase 1b enrolling **AA patients** to assess **hair regrowth and biomarker modulation** (CXCL-9/10, IFN-signature downregulation). - **Vodobatinib**: - After **PROSEEK trial failure** in Parkinson’s (no benefit vs. placebo), focus shifted to **CML**, where it showed over **40% response in ponatinib-resistant patients**. - Exploring head-to-head trial with **bosutinib**, with regulatory discussion for **accelerated approval pathway** under FDA’s **Project Frontrunner**. - **Vibozilimod**: - Topline data expected in **Q4 FY25 (AD)** and **Q1 FY26 (psoriasis)**. - Potential **safer alternative to JAK inhibitors**, avoiding black box warnings. --- ### **Commercial Model & Revenue Streams** SPARC operates a **fully out-licensing model** and does not directly commercialize products. Revenue sources include: - **Upfront payments** (e.g., $20M from Sun Pharma for SCD-044) - **Milestone payments** (e.g., $125M potential for SCD-044; undisclosed sums for Sezaby, Elepsia) - **Royalties on sales** - **FDA Priority Review Voucher (PRV)** – pending favorable outcome of litigation over **Sezaby’s PRDV** (petition filed Feb 2024, decision expected Q4 2025). - **Equity stakes** in spin-outs (e.g., 55% in Tiller Therapeutics). --- ### **Corporate Capabilities** - **R&D Centres**: Mumbai (corporate & discovery), Vadodara (CMC), New Jersey (U.S. operations). - **Global Capability Centres (GCCs)**: - Drive innovation in **computational chemistry**, **bioinformatics**, and **protein engineering**. - Leverage India’s talent pool and high-performance computing for accelerated target identification and lead optimization. - **Internal Biologics Capability**: - Built from scratch between 2021–2024 under Nitin Damle. - Now supports development of **ADCs, bispecifics, T-cell engagers**, and **immunofusions**. --- ### **Strategic Pillars (2025)** 1. **Focus on Oncology & Immunology** – where scientific depth and asset differentiation provide competitive advantage. 2. **Agile R&D Model** – early partnering, NewCos, and milestone-driven capital allocation to reduce financial risk. 3. **Near-Term Value Generation**: - PRV monetization (Sezaby) - Vodobatinib partnership (CML) - Tiller Therapeutics IND filing (FY26) - PDP-716 approval path (target FY26)